Author(s)

Maduike C. O. Ezeibe, Ijeoma J. Ogbonna

Department of Veterinary Medicine, Michael Okpara University of Agriculture, Umudike, Nigeria.

Viral loads (copies of RNA per ml of plasma) of HIV/AIDS patients, who volunteered for clinical trial of the Medicinal synthetic Aluminum-magnesium silicate, were assessed, before and after they were treated. The treatment lasted 4 weeks, 8 weeks and 12 weeks respectively. A patient who could not access approved laboratory for viral load test on time, continued the treatment for 24 weeks. Following treatment with the medicine, mean viral load of HIV/AIDS patients reduced (P < 0.05) from 18875.00 ± 17059.18 to 327.50 ± 226.84. Rates of the viral load reduction were: 86% after 4 weeks, 96% after 8 weeks and 99.71% after 12 weeks. Clinical signs complained of, by the patients during the treatment, included, fever, dermatitis, boils, joint pain, leg edema and sore throat. These clinical signs ceased when they were treated, so that the antiretroviral treatment was completed. The patient who was on the medication for 24 weeks had no adverse drug reaction.

Clinical Trial, Medicinal Synthetic Aluminum-Magnesium Silicate (Nanoparticles), Cure for HIV/AIDS

Ezeibe, M. and Ogbonna, I. (2015) In Vivo Antiretroviral Effects of the Medicinal Synthetic Aluminum-Magnesium Silicate. World Journal of AIDS, 5, 59-65. doi: 10.4236/wja.2015.52007.